The Oncologist, Vol. 9, No. 1, 1324,
February 2004
© 2004 AlphaMed Press
ORIGINAL PAPER Breast Cancer |
Recognition and Management of Hereditary Breast Cancer Syndromes
Darcy L. Thulla,
Victor G. Vogelb
a Magee/UPCI Breast Cancer Genetics Program, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA;
b Magee/UPCI Breast Cancer Prevention Program, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA
Correspondence:
Victor G. Vogel, M.D., M.H.S., Magee/UPCI Breast Cancer Prevention Program, Magee-Womens Hospital, 300 Halket Street, Room 3524, Pittsburgh, Pennsylvania 15213, USA. Telephone: 412-641-6500; Fax: 412-641-6461; e-mail: vvogel{at}mail.magee.edu
Clinicians should recognize the genetic syndromes that predispose to the development of breast cancer so that patients may be afforded the opportunity to have genetic testing to assist them and their family members in making medical management decisions. Approximately 80%90% of hereditary breast cancer cases are caused by mutations in the BRCA1 and BRCA2 genes. Other important clinical genetic predispositions include Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, and ataxia-telangiectasia. The key to identifying women who are at risk for a hereditary breast cancer lies in obtaining an adequate, three-generation family history, including ethnic background. For unaffected women, breast cancer risks can be estimated using the quantitative models of Gail and Claus, but there are limitations to these models. Other quantitative models predict the likelihood that a patient is carrying a mutated gene. Genetic testing is available at selected laboratories for each of the hereditary syndromes described, and there are three possible outcomes to testing. These outcomes and their management implications are described in detail. Clinical management options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic surgery. Application of these principles can reduce morbidity in women with genetic predispositions to breast cancer.
Key Words. Breast neoplasms • Genetic predisposition • Chemoprevention • Tamoxifen • Prophylactic surgery
This article has been cited by other articles:

|
 |

|
 |
 
C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
J. Clin. Oncol.,
January 20, 2009;
27(3):
433 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. B Greer and D. C Whitcomb
Role of BRCA1 and BRCA2 mutations in pancreatic cancer
Gut,
May 1, 2007;
56(5):
601 - 605.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. G. Vogel
Identifying and Screening Patients at Risk of Second Cancers
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2006;
15(11):
2027 - 2032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Kendler
Reflections on the Relationship Between Psychiatric Genetics and Psychiatric Nosology
Am J Psychiatry,
July 1, 2006;
163(7):
1138 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Kaut
Counseling Psychology in the Era of Genetic Testing: Considerations for Practice, Research, and Training
The Counseling Psychologist,
July 1, 2006;
34(4):
461 - 488.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L Wideroff, S T Vadaparampil, M H Greene, S Taplin, L Olson, and A N Freedman
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
J. Med. Genet.,
October 1, 2005;
42(10):
749 - 755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sifri, S. Gangadharappa, and L. S. Acheson
Identifying and Testing for Hereditary Susceptibility to Common Cancers
CA Cancer J Clin,
November 1, 2004;
54(6):
309 - 326.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by AlphaMed Press.
|
|